NCT04494191View on ClinicalTrials.gov

Bioequivalence Study of Flibanserin From AphroFemine 100 mg F.C.T (Bio Med for Pharmaceuticals Industries (BIOMED), Egypt) Versus Addyi 100 mg Tablets (Sprout Pharmaceuticals, Inc., USA)

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

December 12, 2018

Primary Completion Date

December 19, 2018

Study Completion Date

February 27, 2019

Conditions

Healthy

Interventions

DRUG

Flibanserin 100Mg Tab

One tablet contains 100 mg Flibanserin

DRUG

Flibanserin 100 MG [Addyi]

One tablet contains 100 mg Flibanserin

Trial Locations (1)

11511

Genuine Research Center GRC, Cairo

All Listed Sponsors

collaborator

Bio Med for Pharmaceuticals Industries (BIOMED), Egypt

UNKNOWN

lead

Genuine Research Center, Egypt

INDUSTRY

NCT04494191 - Bioequivalence Study of Flibanserin From AphroFemine 100 mg F.C.T (Bio Med for Pharmaceuticals Industries (BIOMED), Egypt) Versus Addyi 100 mg Tablets (Sprout Pharmaceuticals, Inc., USA) | Biotech Hunter | Biotech Hunter